v:* {behavior:url(#default#VML);}
o:* {behavior:url(#default#VML);}
b:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by the disease’s increasing prevalence and high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. However, these novel therapies predominantly represent later-to-market entrants from existing drug classes or novel combination therapies of existing compounds. Among the drug classes expected to undergo the fastest growth are the sodium/glucose cotransporter 2 (SGLT 2) inhibitors—due to the cardiovascular (CV) benefit demonstrated by Jardiance—and the glucagon-like peptide 1 (GLP 1) receptor agonists—due to their efficacy, potential for weight loss, and the CV benefit associated with Victoza and Ozempic. However, these therapies will face major challenges in uptake, including reimbursement hurdles and an increasingly stringent regulatory environment.
QUESTIONS ANSWERED
Following Jardiance’s positive CV results, will SGLT 2 inhibitors surpass the dipeptidyl peptidase (DPP–IV) inhibitors as the most valuable oral drug class?
Boosted by positive CV data, will Victoza continue to lead the GLP 1 receptor agonists in the face of once-weekly agents such as Trulicity and Ozempic?
Will investments by the pharmaceutical industry in novel FDCs such as Xultophy and Soliqua reap rewards?
What do key opinion leaders think about emerging therapies such as sotagliflozin, ITCA-650, and oral semaglutide?
Geographies covered
United States, EU5, Japan
Primary Research
19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other DRG research
Epidemiology
Prevalence of T2D by country with population-specific diagnosed and drug-treatment rates
Forecast
10-year, annualized, drug-level sales and patient share of key T2D therapies through 2029, segmented by brands/generics
Emerging therapies
Phase III/PR: 7 drugs; coverage of select preclinical, Phase I, and Phase II products
Solution Enhancement
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Factors Influencing Drug Selection in Type 2 Diabetes
Treatment Decision Tree for Type 2 Diabetes: United States
Treatment Decision Tree for Type 2 Diabetes: Europe
Treatment Decision Tree for Type 2 Diabetes: Japan
Unmet Need Overview
Current and Future Attainment of Unmet Needs in Type 2 Diabetes
Top Unmet Needs in Type 2 Diabetes: Current and Future Attainment
Emerging Therapies
Key Findings
Pipeline Trends for Type 2 Diabetes
Key Emerging Therapies
Notable Developments in the Late-Phase Pipeline for Type 2 Diabetes
Key Therapies in Development for Type 2 Diabetes
Estimated Launch Dates of Key Emerging Therapies for the Treatment of Type 2 Diabetes
Key Results From Select Clinical Trials Investigating Sotagliflozin for the Treatment of Type 2 Diabetes
Analysis of the Clinical Development Program for Sotagliflozin
Expert Insight: Sotagliflozin
Key Development Milestones for Sotagliflozin in the Treatment of Type 2 Diabetes
Expectations for Launch and Sales Opportunity of Sotagliflozin in Type 2 Diabetes
Key Results From Select Clinical Trials Investigating Bexagliflozin for the Treatment of Type 2 Diabetes
Analysis of the Clinical Development Program for Bexagliflozin
Expert Insight: Bexagliflozin
Expectations for Launch and Sales Opportunity of Bexagliflozin in Type 2 Diabetes
Key Results From Select Clinical Trials Investigating Efpeglenatide for the Treatment of Type 2 Diabetes
Key Ongoing Clinical Trials of Efpeglenatide in the Treatment of Type 2 Diabetes
Analysis of the Clinical Development Program for Efpeglenatide
Expert Insight: Efpeglenatide
Key Development Milestones for Efpeglenatide in the Treatment of Type 2 Diabetes
Expectations for Launch and Sales Opportunity of Efpeglenatide in Type 2 Diabetes
Key Results From Select Clinical Trials Investigating Tirzepatide for the Treatment of Type 2 Diabetes
Key Ongoing Clinical Trials of Tirzepatide in the Treatment of Type 2 Diabetes
Analysis of the Clinical Development Program for Tirzepatide
Expert Insight: Tirzepatide
Key Development Milestones for Tirzepatide in the Treatment of Type 2 Diabetes
Expectations for Launch and Sales Opportunity of Tirzepatide in Type 2 Diabetes
Insulin Icodec/Semaglutide FDC
Insulin Icodec/Semaglutide FDC Profile
Key Ongoing Clinical Trials of Insulin Icodec/Semaglutide in the Treatment of Type 2 Diabetes
Analysis of the Clinical Development Program for Insulin Icodec/Semaglutide FDC
Expert Insight: Insulin Icodec/Semaglutide FDC
Key Development Milestones for Insulin Icodec/Semaglutide FDC in the Treatment of Type 2 Diabetes
Expectations for Launch and Sales Opportunity of Insulin Icodec/Semaglutide FDC in Type 2 Diabetes
Key Results From Select Clinical Trials Investigating Insulin Icodec for the Treatment of Type 2 Diabetes
Key Ongoing Clinical Trials of Insulin Icodec in the Treatment of Type 2 Diabetes
Analysis of the Clinical Development Program for Insulin Icodec
Expert Insight: Insulin Icodec
Key Development Milestones for Insulin Icodec in the Treatment of Type 2 Diabetes
Expectations for Launch and Sales Opportunity of Insulin Icodec in Type 2 Diabetes
ORMD-0801 Profile
Key Ongoing Clinical Trials of ORMD-0801 in the Treatment of Type 2 Diabetes
Analysis of the Clinical Development Program for ORMD-0801
Expert Insight: ORMD-0801
Key Development Milestones for ORMD-0801 in the Treatment of Type 2 Diabetes
Expectations for Launch and Sales Opportunity of ORMD-0801 in Type 2 Diabetes
Key Results From Select Clinical Trials Investigating Imeglimin for the Treatment of Type 2 Diabetes
Analysis of the Clinical Development Program for Imeglimin
Expert Insight: Imeglimin
Key Development Milestones for Imeglimin in the Treatment of Type 2 Diabetes
Expectations for Launch and Sales Opportunity of Imeglimin in Type 2 Diabetes
Early-Phase Pipeline Analysis
Select Compounds in Phase II and Early-Phase Development for Type 2 Diabetes
Key Discontinuations and Failures in Type 2 Diabetes
Access & Reimbursement Overview
Region-Specific Reimbursement Practices
Key Market Access Considerations in Type 2 Diabetes: United States
General Reimbursement Environment: United States
Key Market Access Considerations in Type 2 Diabetes: EU5
General Reimbursement Environment: EU5
Key Market Access Considerations in Type 2 Diabetes: Japan
General Reimbursement Environment: Japan
Appendix
Type 2 Diabetes Bibliography
David Rees, Ph.D.
David Rees, M.Biochem., Ph.D., is a senior analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He has authored reports on osteoporosis, autosomal dominant polycystic kidney disease, pulmonary hypertension, and type 2 diabetes. Previously, he was a postdoctoral research associate at Imperial College London and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize-winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate degree at the University of Bath.
Ansuman Swain
Ansuman Swain, B.D.S., M.P.H.,is an associate epidemiologist at Clarivate. As part of his M.P.H. curriculum, he worked as an intern at the National Health Mission in Odisha, India, where he observed the implementation of the RBSK program. Mr. Swain is a graduate in dentistry from KIIT University in Odisha and holds an M.P.H. degree from Manipal Academy of Higher Education in Karnataka, India, with a specialization in global health from Maastricht University in the Netherlands.